TARAProtara Therapeutics, Inc.同业对比
Protara Therapeutics, Inc. 与SIC 2836 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TARA本股 | $218M#8 | — | 1.4x#3 | 74.1x#12 | — | -28.7%#9 | -2189.6%#11 | -35.6%#5 | — | — | — | — |
| PALI | $304M#1 | 2.7x#1 | 2.5x#6 | — | — | -16.2%#6 | — | -13.8%#3 | — | — | — | — |
| FATE | $298M#2 | — | 1.9x#4 | 44.8x#10 | -51.2%#8 | 26.8%#3 | -2222.4%#12 | -88.8%#9 | -102.3%#2 | — | — | — |
| LCTX | $264M#3 | — | 4.3x#12 | 18.2x#8 | 53.2%#4 | -241.4%#13 | -251.6%#6 | -104.3%#11 | — | — | — | — |
| STRO | $255M#4 | — | — | 2.5x#1 | 65.2%#2 | 15.9%#4 | -154.5%#4 | — | — | — | — | — |
| LIMN | $238M#5 | — | 793.1x#13 | — | — | -187.8%#12 | — | -3395.2%#13 | -170.3%#3 | — | — | — |
| IVVD | $219M#7 | — | 1.2x#2 | 4.1x#3 | 110.5%#1 | 69.1%#2 | -104.0%#2 | -29.0%#4 | — | — | — | — |
| PLX | $216M#9 | 11.7x#2 | 3.0x#7 | 4.1x#2 | -1.2%#5 | -325.2%#15 | -10.4%#1 | -9.2%#2 | -12.3%#1 | 3#1 | — | — |
| AVXL | $224M#6 | — | 2.0x#5 | — | — | -7.8%#5 | — | -41.2%#7 | — | — | — | — |
| ALEC | $209M#10 | — | — | 9.9x#7 | -79.1%#10 | -20.2%#8 | -741.3%#9 | — | — | — | — | — |
| SRZN | $198M#11 | — | — | 57.1x#11 | -67.4%#9 | -280.8%#14 | -1210.6%#10 | — | — | — | — | — |
| ACOG | $191M#12 | — | 3.6x#10 | 18.7x#9 | — | -39.8%#10 | -221.7%#5 | -39.0%#6 | — | — | — | — |
| CHRS | $187M#13 | — | 3.1x#8 | 4.4x#4 | 59.8%#3 | 489.4%#1 | -429.5%#8 | 276.2%#1 | -351.2%#4 | — | — | — |
| ABOS | $187M#14 | — | 3.3x#9 | — | — | -18.6%#7 | — | -211.9%#12 | -421.4%#5 | — | — | — |
| VYGR | $187M#15 | — | 1.2x#1 | 4.6x#5 | -49.5%#6 | -84.2%#11 | -326.6%#7 | -77.6%#8 | — | — | — | — |
| DTIL | $179M#16 | — | 3.9x#11 | 5.2x#6 | -50.1%#7 | -738.0%#16 | -152.2%#3 | -101.0%#10 | — | — | 42.0%#1 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议